Top 10 Companies in the (S)-(-)-N-Methyl-1-phenylethylamine (CAS 19131-99-8) Market (2026): Market Leaders Driving Global Chiral Chemistry

MARKET INSIGHTS

Global (S)-(-)-N-Methyl-1-phenylethylamine (CAS 19131-99-8) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(S)-(-)-N-Methyl-1-phenylethylamine (CAS 19131-99-8) is a chiral secondary amine compound featuring a single stereocenter, widely recognized for its high optical purity and enantioselective properties. As the (S)-enantiomer of N-methyl-1-phenylethylamine, this compound serves as a critical chiral building block and resolving agent in asymmetric synthesis, with applications spanning pharmaceutical intermediates, agrochemical development, and fine chemical manufacturing.

The market is gaining steady momentum, driven primarily by the expanding demand for enantiomerically pure compounds in drug development and the growing emphasis on stereoselective synthesis within the pharmaceutical industry. Furthermore, its role as a chiral resolving agent in the production of active pharmaceutical ingredients (APIs) continues to underpin consistent demand. Key suppliers operating in this space include TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and Alfa Aesar, among other specialty fine chemical manufacturers catering to research and industrial‑scale applications globally.

(S)-(-)-N-Methyl-1-phenylethylamine (CAS 19131-99-8) Market – View in Detailed Research Report

Top 10 Companies in the (S)-(-)-N-Methyl-1-phenylethylamine (CAS 19131-99-8) Market

1. Merck KGaA (Germany)

Merck KGaA is a global leader in pharmaceutical and chemical research, with a robust portfolio of chiral fine chemicals. The company supplies high‑purity (S)-(-)-N‑Methyl‑1‑phenylethylamine for API development and academic research.

Sustainability & Growth Initiatives:

• Investments in green chemistry processes and renewable feedstocks.
• Commitment to reducing carbon footprint across manufacturing sites.
• Enhanced quality management systems to support GMP compliance.

2. Tokyo Chemical Industry Co., Ltd. (Japan)

TCI offers a broad range of specialty chemicals, including chiral intermediates for pharmaceutical and agrochemical sectors. Their (S)-(-)-N‑Methyl‑1‑phenylethylamine is available in multiple purity grades.

Sustainability & Growth Initiatives:

• Development of energy‑efficient synthesis routes.
• Partnerships with academic institutions for advanced chiral synthesis.
• Focus on scalable, cost‑effective production.

3. Biosynth (Switzerland)

Biosynth specializes in the production of chiral building blocks for pharmaceuticals. Their (S)-(-)-N‑Methyl‑1‑phenylethylamine is supplied with rigorous analytical documentation.

Sustainability & Growth Initiatives:

• Adoption of biocatalytic resolution methods.
• Investment in high‑throughput purification technologies.
• Commitment to ISO 9001 and ISO 14001 standards.

4. Enamine Ltd. (Ukraine)

Enamine provides customized synthesis and rapid scale‑up of chiral compounds for R&D and commercial production. Their (S)-(-)-N‑Methyl‑1‑phenylethylamine supports a wide range of asymmetric syntheses.

Sustainability & Growth Initiatives:

• Flexible, on‑demand production to reduce waste.
• Collaboration with global pharma for green chemistry projects.
• Investment in process intensification technologies.

5. Hairui Fine Chemicals Co., Ltd. (China)

Hairui is a leading Chinese manufacturer of chiral fine chemicals, offering high‑purity (S)-(-)-N‑Methyl‑1‑phenylethylamine at competitive prices.

Sustainability & Growth Initiatives:

• Scale‑up of clean synthesis processes.
• Implementation of ISO 9001 quality systems.
• Strategic partnerships with global pharma for supply chain resilience.

6. PharmaBlock Sciences Co., Ltd. (China)

PharmaBlock focuses on chiral intermediates for pharmaceutical development, providing (S)-(-)-N‑Methyl‑1‑phenylethylamine with comprehensive quality documentation.

Sustainability & Growth Initiatives:

• Investment in renewable raw materials.
• Enhanced waste reduction programs.
• Focus on GMP‑grade production for global markets.

7. Combi‑Blocks Inc. (USA)

Combi‑Blocks delivers custom chiral synthesis services, including (S)-(-)-N‑Methyl‑1‑phenylethylamine, tailored to specific project needs.

Sustainability & Growth Initiatives:

• Process optimization to minimize energy usage.
• Collaboration with research institutions for innovative chiral methods.
• Commitment to ISO 14001 environmental management.

8. Capot Chemical Co., Ltd. (China)

Capot provides high‑purity chiral intermediates for pharmaceutical and agrochemical applications, including (S)-(-)-N‑Methyl‑1‑phenylethylamine.

Sustainability & Growth Initiatives:

• Adoption of green solvent systems.
• Focus on scalable, cost‑effective production.
• Implementation of ISO 9001 quality management.

9. Synthonix Inc. (USA)

Synthonix offers advanced chiral synthesis capabilities, including (S)-(-)-N‑Methyl‑1‑phenylethylamine with high enantiomeric excess (>99% ee).

Sustainability & Growth Initiatives:

• Investment in renewable energy for production facilities.
• Development of catalyst‑based resolution methods.
• Commitment to ISO 14001 environmental standards.

10. Finetech Industry Limited (China)

Finetech specializes in fine chemical manufacturing, providing (S)-(-)-N‑Methyl‑1‑phenylethylamine for pharmaceutical intermediates and research labs.

Sustainability & Growth Initiatives:

• Implementation of waste‑minimization protocols.
• Focus on high‑purity, GMP‑grade production.
• Partnerships with global pharma for supply chain integration.

Download FREE Sample Report: (S)-(-)-N-Methyl-1-phenylethylamine (CAS 19131-99-8) Market – View in Detailed Research Report

Get Full Report Here: (S)-(-)-N-Methyl-1-phenylethylamine (CAS 19131-99-8) Market – View in Detailed Research Report

Outlook

The (S)-(-)-N‑Methyl‑1‑phenylethylamine market is expected to continue robust growth, driven by the expanding global pharmaceutical pipeline, regulatory push for enantiomerically pure drugs, and increasing adoption of chiral auxiliaries in agrochemical and fine chemical manufacturing. Supply chain resilience, driven by a concentrated group of high‑purity producers, will support consistent availability and quality, while innovation in green chemistry and process intensification will further enhance market attractiveness.

Future Trends

• Accelerated development of catalytic asymmetric methods reducing reliance on stoichiometric chiral auxiliaries.
• Expansion of chiral resolution technologies in agrochemical and specialty chemical sectors.
• Growth of custom synthesis services catering to niche R&D and early‑stage development needs.
• Increased focus on sustainability, including renewable feedstocks and waste‑minimization in chiral synthesis.
• Enhanced digital traceability and supply‑chain transparency for regulated markets.